inositol has been researched along with Astrocytoma, Grade IV in 13 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality." | 5.43 | Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study. ( Bähr, O; Hattingen, E; Pilatus, U; Ronellenfitsch, MW; Steidl, E; Steinbach, JP; Zanella, F, 2016) |
| " This biochemical information can be processed and presented as density maps of several metabolites, among them N-acetylaspartate (marker of neuronal viability), choline (marker of membrane turnover), creatine (related to the energy state of the cells), myo-Inositol (exclusively found in astrocytes), lipids and lactate (observed in necrosis and other pathological processes) which mean relevant information in the context of brain tumors." | 4.85 | Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. ( Celda, B; Martínez-Bisbal, MC, 2009) |
| "Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality." | 1.43 | Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study. ( Bähr, O; Hattingen, E; Pilatus, U; Ronellenfitsch, MW; Steidl, E; Steinbach, JP; Zanella, F, 2016) |
| "Glycine is a key metabolic intermediate required for the synthesis of proteins, nucleic acids, and other molecules, and its detection in cancer could, therefore, provide biologically relevant information about the growth of the tumor." | 1.37 | Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors. ( Bachoo, R; Choi, C; DeBerardinis, RJ; Dimitrov, IE; Ganji, SK; Maher, EA; Malloy, CR; Mickey, BE; Pascual, JM, 2011) |
| "Using 36 biopsies from patients with brain tumors [12 glioblastoma multiforme (GBM); 10 low-grade (LG), including 7 schwannoma and 3 pylocytic astrocytoma; 7 meningioma (MN); 7 brain metastases (MT), including 3 adenocarcinoma and 4 breast cancer] and 9 control biopsies from patients undergoing surgery for epilepsy, we tested the hypothesis that the presence of glycine may distinguish among these brain tumor types." | 1.36 | High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. ( Andronesi, OC; Black, PM; Mintzopoulos, D; Righi, V; Tzika, AA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| El-Abtah, ME | 1 |
| Wenke, MR | 1 |
| Talati, P | 1 |
| Fu, M | 1 |
| Kim, D | 1 |
| Weerasekera, A | 1 |
| He, J | 1 |
| Vaynrub, A | 1 |
| Vangel, M | 1 |
| Rapalino, O | 1 |
| Andronesi, O | 1 |
| Arrillaga-Romany, I | 1 |
| Forst, DA | 1 |
| Yen, YF | 1 |
| Rosen, B | 1 |
| Batchelor, TT | 1 |
| Gonzalez, RG | 2 |
| Dietrich, J | 1 |
| Gerstner, ER | 1 |
| Ratai, EM | 1 |
| Flores-Alvarez, E | 1 |
| Anselmo Rios Piedra, E | 1 |
| Cruz-Priego, GA | 1 |
| Durand-Muñoz, C | 1 |
| Moreno-Jimenez, S | 1 |
| Roldan-Valadez, E | 1 |
| Kumon, M | 1 |
| Nakae, S | 1 |
| Murayama, K | 1 |
| Kato, T | 1 |
| Ohba, S | 1 |
| Inamasu, J | 1 |
| Yamada, S | 1 |
| Abe, M | 1 |
| Sasaki, H | 1 |
| Ohno, Y | 1 |
| Hasegawa, M | 1 |
| Kurahashi, H | 1 |
| Hirose, Y | 1 |
| Steidl, E | 1 |
| Pilatus, U | 1 |
| Hattingen, E | 1 |
| Steinbach, JP | 1 |
| Zanella, F | 1 |
| Ronellenfitsch, MW | 1 |
| Bähr, O | 1 |
| Kallenberg, K | 1 |
| Bock, HC | 1 |
| Helms, G | 1 |
| Jung, K | 1 |
| Wrede, A | 1 |
| Buhk, JH | 1 |
| Giese, A | 1 |
| Frahm, J | 1 |
| Strik, H | 1 |
| Dechent, P | 1 |
| Knauth, M | 1 |
| Martínez-Bisbal, MC | 1 |
| Celda, B | 1 |
| Righi, V | 1 |
| Andronesi, OC | 1 |
| Mintzopoulos, D | 1 |
| Black, PM | 1 |
| Tzika, AA | 1 |
| Srinivasan, R | 1 |
| Phillips, JJ | 1 |
| Vandenberg, SR | 1 |
| Polley, MY | 1 |
| Bourne, G | 1 |
| Au, A | 1 |
| Pirzkall, A | 1 |
| Cha, S | 1 |
| Chang, SM | 1 |
| Nelson, SJ | 1 |
| Choi, C | 1 |
| Ganji, SK | 1 |
| DeBerardinis, RJ | 1 |
| Dimitrov, IE | 1 |
| Pascual, JM | 1 |
| Bachoo, R | 1 |
| Mickey, BE | 1 |
| Malloy, CR | 1 |
| Maher, EA | 1 |
| Howe, FA | 1 |
| Barton, SJ | 1 |
| Cudlip, SA | 1 |
| Stubbs, M | 1 |
| Saunders, DE | 1 |
| Murphy, M | 1 |
| Wilkins, P | 1 |
| Opstad, KS | 1 |
| Doyle, VL | 1 |
| McLean, MA | 1 |
| Bell, BA | 1 |
| Griffiths, JR | 1 |
| Hagberg, G | 1 |
| Burlina, AP | 1 |
| Mader, I | 1 |
| Roser, W | 1 |
| Radue, EW | 1 |
| Seelig, J | 1 |
| Cheng, LL | 1 |
| Chang, IW | 1 |
| Louis, DN | 1 |
| Castillo, M | 1 |
| Smith, JK | 1 |
| Kwock, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI[NCT02843230] | 30 participants (Actual) | Observational | 2016-08-01 | Completed | |||
| Combination of 11C-MET PET and MRS in the Diagnosis of Glioma.[NCT03009318] | 100 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency[NCT02021526] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn (stopped due to NIH funding resulted in new clinical trial) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for inositol and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Proton magnetic resonance spectroscopy imaging in the study of human brain cancer.
Topics: Aspartic Acid; Brain; Brain Diseases; Brain Neoplasms; Choline; Creatinine; Glioblastoma; Humans; In | 2009 |
12 other studies available for inositol and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma.
Topics: Angiogenesis Inhibitors; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Female; Glioblastoma; Huma | 2022 |
Correlations between DTI-derived metrics and MRS metabolites in tumour regions of glioblastoma: a pilot study.
Topics: Anisotropy; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; Choline; Contrast Media; Creatine; Di | 2020 |
Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy.
Topics: Brain Neoplasms; Choline; Glioblastoma; Humans; Inositol; Isocitrate Dehydrogenase; Magnetic Resonan | 2021 |
Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Brain N | 2016 |
Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy.
Topics: Aged; Brain Neoplasms; Case-Control Studies; Female; Glioblastoma; Glutamine; Humans; Inositol; Magn | 2009 |
High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors.
Topics: Adolescent; Adult; Biomarkers, Tumor; Brain Neoplasms; Glioblastoma; Glycine; Humans; Inositol; Magn | 2010 |
Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.
Topics: Biomarkers, Tumor; Brain Neoplasms; Choline; Glioblastoma; Humans; Image Interpretation, Computer-As | 2010 |
Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors.
Topics: Brain Chemistry; Brain Neoplasms; Glioblastoma; Glycine; Humans; Imaging, Three-Dimensional; Inosito | 2011 |
Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy.
Topics: Alanine; Aspartic Acid; Astrocytoma; Brain Neoplasms; Choline; Creatine; Glioblastoma; Humans; Inosi | 2003 |
In vivo proton MR spectroscopy of human gliomas: definition of metabolic coordinates for multi-dimensional classification.
Topics: Adult; Aspartic Acid; Astrocytoma; Brain Neoplasms; Choline; Cluster Analysis; Creatine; Discriminan | 1995 |
Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens.
Topics: Amino Acids; Brain; Brain Neoplasms; Glioblastoma; Humans; Inositol; Lipid Metabolism; Magnetic Reso | 1998 |
Correlation of myo-inositol levels and grading of cerebral astrocytomas.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Child; Chil | 2000 |